

# CEPI | New vaccines for a safer world

Coalition for Epidemic Preparedness Innovations

## Newsletter 14 July 2017

---

### Address from CEO

It has been an extraordinary week, one full of fireworks, for CEPI.

On Saturday morning, in her opening remarks at the health section of the G20 Leaders' Summit in Hamburg, Prime Minister Erna Solberg announced that Norway would increase the amount it has committed to CEPI by NOK 600 million, or \$70 million. On the same day, Canada announced that it had joined the Coalition with an initial contribution of C\$4 million (\$3 million).

CEPI was also called out by name in the *G20 Leaders' Declaration*. The Declaration addresses many of the challenges faced by an interconnected world, including the need to strengthen health systems and safeguard against health crises. To this end, it expressed the Leaders' support for WHO, the implementation of the International Health Regulations, the establishment of rapid financing mechanisms, and fostering R&D preparedness through "globally coordinated models as guided by the WHO R&D Blueprint, such as the Coalition for Epidemic Preparedness Innovations (CEPI)."



On Tuesday and Wednesday, in Berlin, the German Federal Ministry of Education and Research hosted the fourth meeting of CEPI's Interim Board, with Minister Johanna Wanka addressing the Board on the second day and conveying her strong appreciation of CEPI's work. The most significant item the Board considered was the Secretariat's proposal regarding CEPI's future governance, which was approved subject to some comparatively minor revisions. The Board also endorsed CEPI's investment strategy, approved our plans for the Secretariat (following a healthy discussion about how to scale this body appropriately), approved CEPI's clinical trials policy and provided helpful and concrete guidance on the issue of rapid response planning. A summary of the meeting and its outcomes is in preparation and will be released shortly.

On the same day, back in Oslo, we received the full and final proposals for our call to develop MERS, Lassa, and Nipah vaccines. These proposals will now enter intensive review in anticipation of the Scientific Advisory Committee's final ranking and recommendations at its meeting in August.

The CEPI team has been working hard for months to bring our resource mobilization, our strategic planning, and our vaccine development efforts to these milestones. I am extremely proud of what they've accomplished and wish them, and all of you, a happy summer holidays.

*Richard Hatchett, CEPI CEO*



**Follow CEPI on Twitter @CEPIvaccines**



**Visit the CEPI website**

---